Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Sinopharm Group Co's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $10,413 Mil. Sinopharm Group Co's Total Assets for the quarter that ended in Jun. 2024 was $59,214 Mil.
Therefore, Sinopharm Group Co's Equity to Asset Ratio for the quarter that ended in Jun. 2024 was 0.18.
The historical rank and industry rank for Sinopharm Group Co's Equity-to-Asset or its related term are showing as below:
SHTDY'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.16 Med: 0.19 Max: 0.22
Current: 0.18
During the past 13 years, the highest Equity to Asset Ratio of Sinopharm Group Co was 0.22. The lowest was 0.16. And the median was 0.19.
SHTDY's Equity-to-Asset is ranked worse than 86.36% of 110
companies
in the Medical Distribution industry
Industry Median: 0.435
vs SHTDY: 0.18
Sinopharm Group Co Equity-to-Asset Historical Data
The historical data trend for Sinopharm Group Co's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sinopharm Group Co's Equity-to-Asset
For the Medical Distribution subindustry, Sinopharm Group Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co's Equity-to-Asset Distribution in the Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Equity-to-Asset falls into.
Sinopharm Group Co Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Sinopharm Group Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co (OTCPK:SHTDY) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Sinopharm Group Co Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Sinopharm Group Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2023. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SHTDY has been successfully added to your 